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CHAPTER I 
 
INTRODUCTION 
 
 Clinical decision support (CDS) in electronic prescribing (e-Rx) systems can improve patient 
safety and quality of care (1, 2). Despite the availability of  drug information knowledgebases and 
decision support modules, systems containing this functionality often have it disabled or customized 
to minimize irrelevant or insignificant alerts, due to concerns about alert fatigue, i.e., decreasing the 
“attention cost” of alerts (3). We postulate that novel user interfaces may decrease the “attention 
cost” of  alerts, as has been shown in inpatient CPOE (1). This study aimed to explore alternative 
approaches to display alerts, and examine whether and how human factors based interface design 
can be used to improve signal detection from noisy data (alerts and reminders) in an existing e-
prescribing system 
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CHAPTER II 
 
BACKGROUND 
 
Introduction 
 The calls for universal electronic prescribing (e-Rx) are louder than ever (1, 2, 4). Actions 
should be taken to encourage physicians’ adoption. Current estimates suggest that between 5% and 
18% of  clinicians use e-Rx (2, 4). However, despite increasing calls for the use of  electronic 
prescribing by groups such as the Institute of  Medicine (5) and the eHealth Initiative (2, 4), e-
prescribing adoption has not reached the levels called for by the federal government (6). It is widely 
believed that poor design of  clinical decision support in these systems is a large part of  the barrier 
to adoption (2, 4). Issues such as a large number of  alerts leading to ignoring important alerts - 
called “alert fatigue”, and user interfaces that disrupt the work process and require inordinate time 
to comprehend (i.e., increasing the “attention cost” of  the prescribing process) are among the 
challenges yet to be overcome. The goal of  this project is to explore the potential of  novel user 
interface designs to improve the presentation and comprehension of  clinical decision support during 
e-prescribing.  
 
E-Prescribing 
 In the United States, prescription medications are central to health care. According to the 
eHealth Initiative 2004 formal report (2, 4), more than 3 billions prescriptions are written annually, 
accounting for 13% of  health care expenditures and being used by 65% of  the U.S. population. The 
erroneous use of  prescription medications (such as incorrect dosages, drug-drug interactions or 
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drug-allergy interactions) is common and often results in patient injuries. In general, injuries from 
medications are termed adverse drug events (ADEs). A study found that 4.3% of  patients 
experienced ADEs, 83% of  which resulted from outpatient prescriptions. Another study of  62,216 
emergency department visits found that 1.7% of  visits resulted from outpatient ADEs. A meta-
analysis of  36 studies concluded that 5% of  hospital admissions resulted from outpatient ADEs and 
only 23% were due to patient errors (3). Center for IT Leadership (CITL) ’s report on ambulatory 
setting CPOE systems estimated 8 millions ADEs in U.S. per year; more than 3 millions were 
preventable; this is equal to 38 ADEs per provider-year and on average 14 were preventable per 
provider-year (7). 
 Electronic prescribing, often abbreviated as e-prescribing or e-Rx, is "computer-based 
support for the creation, transmission, dispensing, and monitoring of  pharmacological therapies" (1). 
e-Rx is the use of  computing devices (clinical workstation, personal computer, or handheld devices) 
and drug information knowledgebases to enter, modify, review, output or communicate drug 
prescriptions (2). e-Rx is a form of  computerized physician order entry (CPOE) and is available in a 
variety of  graduated levels ranging from basic prescription entry to linked additional electronic drug 
references, to advanced integration into an EHR (2, 4, 7). Theoretically, e-Rx with integrated 
decision support can reduce medication errors and ADEs, improve health care efficiency and patient 
safety (2-4). 
 
Clinical Decision Support and E-Prescribing 
 In healthcare areas, clinical decision support has been defined somewhat differently by 
different authors or groups (8-13). Teich, et, al. defined “clinical decision support” in CPOE/e-Rx 
systems as “‘providing clinicians or patients with clinical knowledge and patient-related information, 
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intelligently filtered and presented at appropriate times, to enhance patient care”’ (10). This 
functional term includes not only the familiar reactive alerts and reminders (such as alerts for drug 
allergy conflicts and drug–drug interactions), but also many other intervention types, including pick 
lists, structural order sets, medication reference information for prescribers and patients, and any 
other guideline support that can promote safety, education, workflow improvement, and improved 
quality of care.  
 Clinical drug alert/reminder is a form of  clinical decision support. Clinical alert/reminder 
systems have been the central tools used with e-Rx systems. These systems use computer-generated 
messages that notify prescribers when their actions may be potentially unsafe. Typically, e-Rx 
systems provide decision support in many areas, including (2, 7, 9, 10):   
z Drug-allergy interaction 
z Drug-drug interaction 
z Drug-disease interaction 
z Drug-lab interaction 
z Drug-food interaction 
z Drug-herbal remedy/vitamin interaction 
z Duplicate ingredient 
z Recommended dosing limits including patient-specific limits on total dose, dose rate, etc. 
z Geriatric precaution 
z Lactation precaution 
z Pediatric precaution 
z Pregnancy precaution 
z Structural order sets 
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z Drug reference information including formulary information, insurance information, cost, 
generic alternatives 
z National/institutional/departmental guidelines that can promote safety, education, workflow 
improvement, communication between different stakeholders, and improved quality of care, 
etc. 
 In general, drug alerts/reminders are triggered based on pre-defined rules from CDS 
modules embedded in or connected to e-Rx systems. e-Rx writing tools promise to deliver safe and 
effective care, in part through their ability to influence clinician decision-making by displaying 
patient-specific alerts. They also can help make clinical data readily available and reduce the time a 
prescriber needs to spend accessing data – giving a prescriber more time with the patient, and 
potentially allowing the prescriber to provide better care. 
 
Barriers to e-Prescribing Adoption 
 Despite the availability of  commercial drug information knowledgebases and CDS modules, 
users often disable this functionality. The reasons for this appear to fall within two main themes: the 
perceived insignificance of  the alerts; and the poor integration of  alerts into workflow(2-4, 14, 15)..  
Each of  these barriers will be discussed below.  
 
Signal-to-Noise issues 
 Issues of  workflow integration are made more significant when the drug alerts are not 
considered important. Numerous studies have demonstrated extremely high override rates, far and 
above the probably of  relevance proposed by Johnson and Grundmeier (16). For example, Payne, et 
al., studied characteristics and clinicians’ override of  42,641 prescription orders and about 4500 
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safety checks associated with those prescriptions from a practitioner order entry system in a VA 
hospital (17). They discovered an 88% override rate for drug interaction alerts and a 69% override 
rate for drug-allergy interaction alerts.  Isaac, et al., in a recently published study, looked at 233,537 
medication safety alerts associated with 3.5 million electronic prescriptions generated by 2,872 
physicians at community-based outpatient practices in Massachusetts, New Jersey and Pennsylvania 
(18). They found that, of  those 233,537 alerts, 98.6% were for a potential interaction with a drug 
being taken by a patient, but physicians overrode 93.4% of  the drug interactions and 77% of  the 
drug allergy alerts. 
 The high override rate suggests that most prescribers do not find currently implemented, 
intrusive alerts valuable, and that major changes are needed to improve the usefulness of  electronic 
medication alerts.  This was proposed by Weingart, in his study of physicians’ override rates for 
3,481 drug allergy and drug interaction alerts in primary care (19). Physicians overrode the majority 
of  alerts for drug allergies (91.2% override rate) and drug interactions (89.4% override rate), and no 
significant number of  ADEs occurred, suggesting that the threshold for alerting was set too low or 
that the signal-to-noise rate of  drug alerts was low (or both.) They recommended, for example, that 
e-Rx applications should suppress alerts for renewals of  medication combinations that patients 
currently tolerate. 
 
Workflow Integration Issues 
 Studies have previously demonstrated that CPOE success depends upon several factors, 
including clinicians’ access to CPOE systems that are integrated into a uniform information 
workflow (1, 9, 20). Miller and colleagues(9) summarized multiple mechanisms for delivering 
decision support within the context of  CPOE systems. Three important axes were identified for 
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delivering decision support content: the role for decision support, the time to intervene, and the 
method to intervene. According to these studies, decision support may be integrated into the 
workflow in 2 presentations styles. Those styles include: 
 
1. Intrusive presentation. An example of  intrusive presentation is shown in Figure 1. With 
this type of  drug alert presentation, the prescriber is required to generate a response 
before continuing the ordering process. 
 
 
Figure 1: Intrusive pop-up window text to deliver drug alert (21) 
 
2. Actionable presentation. An example of  actionable presentation is shown in Figure 2. 
This type of drug alert presentation allows the prescriber to consider and choose (or not) 
the recommended action within the alert window itself. 
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Figure 2: Actionable options in subpane to deliver guidelines for best  practice (9) 
 
 A more complex form of  decision support may combine different presentation styles 
together and integrate patient-specific information (patient demographics, diagnosis, laboratory 
results, active orders, guidelines, protocols, etc.) (9). Depending on the type and severity of  the alert, 
one or another presentation styles may be most appropriate. A study by Rosenbloom and Miller (20) 
evaluated the relationship between physicians’ override rates and different drug alert presentation 
methods.  The use of  an intrusive presentation method, while providing clinically important 
information, did so at a significant workflow cost to prescribers. A “pop-up” alert in a separate user 
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interface window was viewed by users as disruptive, and should be reserved for only the most severe 
clinical indications.  
 
A Case Report:  First Databank Commercial Knowledgebase 
 To understand the volume of  clinical drug alerts generated by commercial drug information 
knowledgebases, a prototype e-Rx application was developed using a connection to the First 
DataBank® (FDB) drug information knowledgebases. This prototype allowed the user to screen 
prescribed medications for 13 decision support modules including Drug Allergy Conflicts (DAM), 
Disease Contraindications (DDCM), Drug-Drug Interactions (DDIM), Drug-Food Interaction 
(DFIM), Duplicate Ingredient (DI), Dose Range Checking (DOSE), Duplication of  Therapy (DT), 
Geriatric Precautions (GERI), Lactation Precautions (LACT), Pediatric Precautions (PEDI), 
Pregnancy Precautions (PREG) and Side Effects (SIDE). Figure 3 shows the interface of  prototype 
application. In our feasibility tests, a mock-up patient profile with only 2 diagnosis, 2 allergies, and 10 
medications triggered 49 clinical drug alerts with the 5 screening modules in the First DataBank® 
drug information knowledgebases (Nov. 2003 version). Similarly, a mock-up patient profile with 6 
diagnosis, 2 allergies, and 10 medications triggered more than 150 clinical drug alerts if  9 screening 
modules were selected. According to domain expert clinicians, many of  these drug alerts were of  
low clinical significance. We concluded that the number of  alerts triggered by this commercial drug 
information knowledgebases was considered unbearable therefore would be treated as “noise” by 
prescribers. Moreover, given the large number of  alerts, the few clinically significant alerts are more 
likely to be overlooked (a problem of  low signal-to-noise ratio). 
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Figure 3: The interface of  prototype e-Rx application 
 
The role of  Human Factors Research 
 Many authors (2-4, 14, 22-26) list the major usability guidelines for achieving a successful e-
Rx product. Although all of  usability guidelines listed in the literature may be important to effective 
design, the scope of  proposed study and task requirements compelled us to focus on those deemed 
critical to the study objectives (described below): 
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 1. Efficiency. Physicians are generally under significant fine pressure and want to spend less 
time accessing data and more time with their patients. In reality, it is difficult to convince a physician 
that clicking through menus and choosing from options is more efficient than simply scribbling 
some words on a pad of  paper. However, through our literature review and contextual inquiries, we 
found that the majority of  physicians’ time is not actually spent writing the prescription itself, but 
rather on researching information in order to write a prescription and maintaining the prescription 
record. Therefore, a design that reduces information retrieval while not impacting prescription 
writing time is essential to a successful product. 
 2. Information density. There is a trade-off  between a design that does not crowd too much 
information per screen (excessive information density) and the need to display as much information 
as needed on one screen. Physicians want a comprehensive system with ready access to key 
information. They prefer an effective but simple user interface to minimize cognitive burden and to 
reduce the risks of  errors. The e-Rx systems can predispose to use errors, such as selecting a sound 
alike but wrong medication from a pick list or prescribing for the wrong patient due to a failure to 
exit the previous patient’s record (25). For high volumes of  information such as comprehensive drug 
references, it may be better to split up the information in a logical manner, such as general 
information, drug conflicts, and drug dosages and display them in different areas of  the screen.  
 3. Freedom of  user control. It may be better to let the users decide what kind of  
information they need most. Users could select different decision support modules and decide how 
to display various types of  clinical alerts on the screen. Moreover, on every page of  the prescription 
writing process, it may be a good idea to provide the option to cancel the current prescription that a 
physician is writing, or provide an alternative suggestion for the replacement. This feature will 
provide more flexibility for the e-Rx users (2, 4, 25). 
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 4. User-centered Design (27). It is well known that a commercial drug information 
knowledgebase can provide comprehensive drug reference but generates low signal-to-noise 
information, as described above. Visualization and evaluation techniques are available to facilitate the 
design of  user interfaces, and have demonstrated an ability to improve users access to and 
understanding of  large amounts of  information (28-30). In addition, careful use of  intrusive delivery 
methods like “pop-up” window, and less intrusive delivery methods like in-line “incidental display of 
relevant information”, should be better aligned with the types of  alerts presented to prescribers (1, 
9). Of  note, there is virtually no literature examining the presentation and prioritization of  multiple 
drug alerts. Given the massive number of  drug alerts that commercial drug information 
knowledgebases can produce the low signal-to-noise ratio of  these alerts, it is very important to 
assess how different alerting interfaces can impact delivery and organization of  multiple drug alerts 
in an e-Rx application. This assessment is the goal of  this study. 
In this study, we only focused on user interface design and evaluation for outpatient e-Rx using 
a typical desktop PC-based system. The study may also provide information applicable to the use of  
PDA-based systems, which have better mobile performance but are less functional than desktop PC 
platforms. 
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CHAPTER III 
 
INTERFACE DEVELOPMENT AND EXPERT REVIEW 
 
Introduction 
 In the previous chapters, I noted the challenge of  low signal-to-high noise ratio of  
medication alerts and the potential for attention to usability factors to improve e-Rx systems. In 
particular, specific aspects of  usability such as efficiency, error presentation, information density, and 
freedom of  user control may be important to explore as we seek to improve the delivery of  
medication alerts. 
 We postulate that novel user interfaces may be required to decrease the attention cost of  
alerts in the outpatient setting. In this study, attention cost is defined as prescriber’s effort or 
amount of activity to get the e-Rx work done accurately and completely. At least one inpatient 
computerized physician ordering entry system had focused on a similar approach with good results 
(1). 
 This study was designed to explore alternative approaches for displaying clinical drug alerts 
in an outpatient e-Rx system. The study was broken into three specific aims.  This chapter will 
explore the process and results of  the First Aim: Using a user-centered design, iteratively build, 
evaluate and refine a series of  user interfaces to display alerts based on available human-computer 
interface. 
 
Methods 
 Four methods were employed to develop these candidate user interfaces. First, existing 
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literature about human-computer interfaces was explored to discover specific user interface 
approaches that have been developed for multi-dimensionality alerting. PubMed database, ACM 
(Association for Computing Machinery) digital database and SIGCHI (Special Interest Group on 
Computer-Human Interaction) database were searched. The combination of  the terms used 
included: (electronic prescription OR e-prescription OR e-Rx) AND (system OR model); (electronic 
prescription OR e-prescription OR e-Rx) AND (user interface OR interface design); (drug alert OR 
medication alert OR drug reminder) AND (user interface OR interface design OR presentation); 
(alert OR reminder) AND (information visualization). We briefly reviewed the abstracts of  relevant 
articles and retrieved the full-text articles that might contribute to developing the drug alert interface 
in an e-Rx system.  
 Second, we completed a process called information mapping based on common information 
axes available in existing drug information knowledgebases. Information mapping is a scientific 
methodology used to divide and label information for easy comprehension, use, and recall (31). In 
the context of this study, we mapped the drug alert attributes (category of alert, severity, frequency, 
strength of evidence, etc.) to different metaphors (color, text, icon and shape) to ensure that the 
drug alert content could be readily captured and comprehended by clinician prescribers. 
 Third, we used the mapping results to construct a prototype clinical decision support 
interface designed to present multiple drug alerts generated from commercial First DataBank® drug 
information knowledgebases. This application was developed using Java/Oracle programming, and 
allowed us to explore knowledgebase output with predefined complex cases; the prescriber could 
explore different alert presentation formats that present the same set of  medication alerts. I used 
our 4 interface concepts to construct the prototype:  
• Interface concept #1: text based alert presentation 
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• Interface concept #3: tree based alert presentation 
• Interface concept #4: tree-dashboard based alert presentation 
• Interface concept #2: thermometer based alert presentation 
 Each of  these is more fully described later in the results section. 
 Finally, to access overall clinician perception about the drug alert presentation interfaces, we 
conducted an Expert Review. This study consisted of  presenting screen snapshots from our 
prototype to a group of  prescribers, based on patient scenarios tested during the third phase of  this 
aim. We used a convenience sample of  6 expert reviewers (32), consisting of  faculty/fellow 
members from the Department of  Biomedical Informatics, VUMC. All participants were active 
practitioners with at least 2 years experience working with EHR and e-Rx systems. For this final 
phase, the researcher met individually with each domain expert and used a think-aloud method while 
asking the experts a series of  questions (33). For each interface, two types of  questions were asked: 
1. You are prescribing a medication and are presented with the display above. What does 
this display mean? Choose the most precise answer. 
z The patient has an allergy to a medication 
z The prescriber is trying to prescribe a medication to which the patient may be 
allergic. 
z The patient is receiving an overdose of  Lortab 
 OR 
2. You are prescribing a medication and are presented with the display above.  
z Describe what is happening in this picture? 
z What do the different elements on this page mean? 
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 Each participant received a 14-page storyboard, including cover page, tutorial and snapshots 
of  the e-Rx application (4 interface concepts, 2 snapshot pictures each, randomly ordered). A copy 
of  the storyboard is provided in Appendix A. During the interview, the domain experts were asked 
to review and rank order the 4 interfaces in terms of  clarity and ease of  use. The participants were 
also asked to comment on any issues related to multiple drug alert presentation. 
 
Data Analysis 
 We analyzed the survey questionnaires to assess accuracy of  the interpretation (i.e., the fact 
that a Lortab-associated drug-food alert, not a drug-allergy alert, was delivered to screen), in addition 
to a subjective assessment of  the interface to evaluate if  the alerts were easy to interpret, 
comprehensive, efficient, and discriminating (easy to catch critical information). 
 
Results 
Alternative approaches to display drug alerts 
 Initial literature and computer-human interface review identified a series of  interface 
approaches. Four potential interface approaches appeared to show promise - ScrollText, Tree, 
TreeDashboard, and Thermometer - for information mapping and further application 
implementation (described below in details). Screen views of  these approaches are shown in Figure 
4. 
 ScrollText is a user interface that presents drug alert information in plain text format and in 
an essentially linear way (34). The presciber can vertically scroll the text back-and-forth to locate 
various indicators. "Scrolling", as such, does not change the layout of  the text or metaphors, but 
more or less facilitates the navigation of  various drug alerts. 
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 Tree is a user interface that presents drug alert information hierarchically (35). The hierarchy 
level of  various drug alerts is shown by indentation on the left side of  the Tree nodes. The tree is a 
collection of  one or more nodes. Each node represents a screening module, e.g. drug-drug 
interaction screening, drug-disease ccontraindication screening. Each node is the parent of  zero or 
more children, which are also nodes corresponding to multiple drug alerts retrieved from a certain 
screening module. A tree can be expanded (expanded nodes show their children) or collapsed 
(children are hidden). The way in which a collapsed or expanded node is displayed depends on 
definitive filtering rules. 
 TreeDashboard is a user interface that, at the cost of  some visual and programming 
complexity, shows the hierarchy of  items, plus a matrix of  additional data or item attributes in one 
unified structure. In this study, TreeDashboard-View assembles the information from multiple 
components into a unified display and presents multiple drug alert information in a way that is easy 
to read, and easy to interact during e-Rx. It also allows the prescriber to see a summary of  various 
indicators. TreeDashboard is based on the concept of  TreeTable (35), but it is more interactive in 
the way that the end users’ decisions, preferences and needs could be executed while the user is 
interacting with various indicators. 
 Thermometer is a user interface that presents multiple drug alerts in visualization of  
various thermometers (36, 37). Clinicians are all familiar with thermometers and may be more 
sensitive than anyone else on the changes of  a thermometer metaphor. In this implementation, each 
drug alert was represented by a thermometer metaphor; the drug alert attributes was presented by 
thermometer’s characteristics: mercury’s height, stem’s colour, thermometer’s width, etc. 
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ScrollText-View 
 
Tree-View 
 
TreeDashboard-View 
 
Thermometer-View 
 
Figure 4: Drug alert presentation methods - Scrolltext, Tree, TreeDashboard, Thermometer-View 
 
 
19
 
Information Mapping 
 Five drug alert attributes were included in our information mapping and are shown in Table 
1. A sixth attribute (strength of  evidence) was available in some knowledgebases and was included 
because of  its potential value to clinicians. The mappings of  the six attributes to our four 
representative interfaces are shown in Table 2. The final prototypes for each of  4 interface 
approaches are displayed in Figure 4. 
 
Attribute Description 
Type Category of  drug alert, based on various screening modules defined in FDB drug 
information knowledgebases, consisting of  drug-drug, drug-food, drug-disease, 
drug-indication alerts, and dosing, lactation, pediatric, pregnancy, side effect and DT 
warnings.   
Severity Severity of  the interaction or contraindication (retrieved from FDB drug 
information knowledgebases) 
Frequency Frequency/prevalence of  the interaction or contraindication (retrieved from FDB 
drug information knowledgebases) 
Strength of  
evidence 
Strength of  evidence supporting the warning (FAKE DATA—shown for 
demonstration purposes only) 
Description Description of  the interaction found 
MONO Monograph, which includes detailed information on drug’s adverse reactions, 
contraindications, pharmacokinetics as well as related drug monograph topics 
(retrieved from FDB drug information knowledgebases if  there exists) 
 
Table 1: Description of  drug alert attributes 
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 Scrolltext-
View 
Tree-View TreeDashboard-View Thermometer-View 
Category of  
Alert 
Each subpane 
contains one 
type of  alerts 
Each tree 
node contains 
one type of  
alerts 
Each tree note 
contains one type of  
alerts 
Text around 
thermometer 
Severity Colored text in 
the result 
panel 
Face icon 
Red: Severe 
Yellow: 
Moderate 
severe 
Blue: Mild 
severe 
Green: 
Minimal (OK) 
White: None 
Face icon 
leaf: 
Red: Severe 
Yellow: Moderate 
severe 
Blue: Mild severe 
Green: Minimal (OK) 
White: None 
Liquid color 
Red: Severe 
Yellow: Moderate severe 
Blue: Mild severe 
Green: Minimal (OK)  
White: None 
Frequency Colored text in 
the result 
panel 
Number after 
face icon in 
each tree leaf 
Number after face 
icon in each leaf  OR 
Number in column 
Height/color of  liquid in 
thermometer stem 
Strength of  
Evidence 
Colored text in 
the result 
panel 
Number after 
face icon in 
each leaf 
Number after face 
icon in each leaf  OR 
Number in column 
Number/color in 
thermometer bulb; or 
height/color of  liquid of  
thermometer stem 
Brief  Text 
(Title) 
Colored text in 
the result 
panel 
Text in each 
tree leaf 
Text in each tree leaf Text in or around 
thermometer 
Detail Text Colored text in 
the result 
panel 
Text in the 
subpane 
Text in the subpane Text around 
thermometer or in 
subpane 
Alternatives Colored text in 
the result 
panel with 
links 
Text in the 
subpane with 
links 
Text in the subpane 
with links 
Text around the 
thermometer or in 
subpane with links 
Navigation Tabs, Scroll 
panel, mouse 
cursor, 
Keyboard 
Tabs, mouse 
cursor, 
keyboard, 
subpane 
Tabs, mouse cursor, 
keyboard, subpane 
Tabs, mouse cursor, 
keyboard 
 
Table 2: Drug alert attributes that have been mapped to each potential interface approach 
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Expert Review and Evaluation 
 A prototype e-Rx application was then programmed using Java and Oracle, implementing 
decision support using all 13 screening modules provided by commercial FDB drug information 
knowledgebases. Figure 5 displays the screen snapshot of  e-Rx prototype application. The user 
interface of  e-Rx application was divided into two parts: a Rx writer on the left, and a clinic alert 
collector on the right. After the user inputs new medication(s) or selects one of  several predefined 
complex cases from the bottom left side of  screen, and clicks the “Check ADE” button (cursor 
arrow in Figure 5), the clinical drug alert information is displayed on the right side of  screen. 
 
 
Figure 5: the screen snapshot of  e-Rx prototype application 
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 Six domain experts we invited all agreed to participate the study. Participants received a 14-
page storyboard, including cover page, tutorial and snapshots of  the e-Rx application (4 interface 
concepts, 2 snapshot pictures each, randomly ordered). All subjects reviewed all 4 drug alert 
presentation interfaces and then filled out the questionnaires. Each subject answered his/her drug 
alert related questions correctly. Subjects’ perceptions about the various drug alert presentation 
interfaces are summarized in Table 3. 
 
Interface to present multiple 
ADEs 
ScrollText- 
View Tree-View 
TreeDashboard
-View 
Thermometer- 
View 
Interface concept most textual less graphical more textual 
less textual 
more graphical most graphical
Cognitive style for  
drug alert presentation text-reader 
 
image-visualizer
Easy to catch critical 
information? + ++ ++++ + 
Easy to interpret? ++++ ++++ ++++ − 
Is interface 
compact? − ++ ++++ + D
om
ain
 e
xp
er
t 
A
ss
es
sm
en
t 
Information 
sufficient to make 
order decision? 
++ ++ +++ − 
 
Table 3: Comparison of  prototype interfaces 
 
 Domain experts favored a drug alert presentation interface in which they could quickly 
locate critical information related to each drug alert. Display of  critical alert attributes, ease of  
interpretation, sufficient patient-related and drug-related information, and fast navigation among 
various alerts were considered major factors by the domain experts evaluating the usability of  the 
alert presentations during e-Rx practice. Domain experts believed that an interface that uses both 
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text and intuitive graphics metaphors better achieved the implementation goals. 
 
 Conclusion 
 We were able to map existing alert attributes to prototype user interfaces. Our review results 
suggested that domain experts preferred a presentation method that used both text and graphics to 
depict critical information related to each drug alert. The TreeDashboard-View appeared to be the 
preferred prototype interface in this study (Table 3). 
 We used this feedback in subsequent work, as described in the next chapter. 
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CHAPTER IV 
 
SYSTEM IMPLEMENTATION AND FORMAL USABILITY TESTING 
 
Introduction 
 We postulated that novel user interfaces may be needed to dramatically decrease the 
“attention cost” of  presenting clinical drug alerts in an e-Rx system. We had been able to map 
existing drug alert attributes (Category of  alert, Severity, Frequency, Strength of  Evidence, 
Description, Monograph) to prototype user interfaces as described in Chapter III, Table 2. Our 
Expert Review results suggested that domain experts preferred a presentation method that uses 
both text and graphics to depict critical information related to each drug alert. The TreeDashboard-
View display appeared to be most favored among the four prototype interfaces studied.  We used 
this information to address the following two aims, which will be described below: 
1. Develop a robust prototype of  the preferred user interface from Aim 1 (described in 
Chapter III) and integrate it into an existing e-prescribing platform. 
2. Compare prescriber performance using a standard text display with performance using 
this preferred user interface, with particular focus on clinical appropriateness of  
prescriber’s prescribing response, response time,  prescriber’s preference on two 
interfaces. 
Before the application implementation, we also added one more drug alert attribute (showed 
in Table 4) into our information mapping based upon the feedback we received from Expert Review 
study.  
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Attribute Description 
Clinical effect Pharmacological mechanism of  interaction or contraindication (retrieved 
from FDB drug information knowledgebase) 
 
Table 4: Clinical effect 
 
Prototype Development 
 We implemented our prototype drug alert application into an existing system, Starpanel, that 
includes an e-prescribing application called RxStar. StarPanel is an electronic health record 
application deployed throughout VUMC. It integrates patient data from multiple sources that 
include demographics, lab results, radiology/cardiology/pathology reports, physician notes, 
physician letters, discharge summaries, problem lists, medication log, patient indicators/alerts, 
inpatient/outpatient/ED census, and external test results. It is fully integrated with RxStar. This 
allows access to all of  the electronic patient clinical information from one single screen. StarPanel 
also support various ways to record the patient’s data, as well as workflow via message basket, work-
lists, new results, draft-and-sign, whiteboards, indicator, and consulting service, etc. StarPanel brings 
detailed patient-related information, at the moment that clinicians treat the patient, record the data, 
and communicate other clinicians. 
 RxStar is a web-based outpatient prescription writer designed to create a safe and efficiently 
generated prescription. It contains features designed to improve patient safety, including drug-allergy 
and drug-dose checking. RxStar is used throughout VUMC, allowing approximately 2000 prescribers 
to generate over 60,000 prescriptions each month.  Because RxStar has been well-adopted, it 
represented the best platform to test the additional functionality of  the clinical alert prototype. 
 The alert prototype interface retrieved patient medication information from RxStar (via 
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StarPanel), as well as drug alert information from First DataBank® drug information 
knowledgebases augmented with additional knowledge for certain attributes (e.g. Strength of  
Evidence) to simulate an integrated prescribing and decision support process. RxStar integration 
allowed the application to turn alerts on or off  based on known patient information, such as age, 
weight, medical conditions (diagnosis), and current or new medications. The drug alert information 
was delivered to clinicians in real-time. In addition, the survey collection process was implemented 
directly into the drug alert prototype to calculate time-to-decision and other variables in the 
prescribing workflow as close to the decision point as possible.  
 The prototype was implemented using Perl and Javascript. Specifically, we introduced 
TreeDashboard-View (showed in Figure 6, details are described in Chapter III) and an additional 
standard text-based TextScrolling-View (showed in Figure 7, details are described in Chapter III) as a 
control interface.  Figure 8 shows the prescription writer and drug alert prototype.  
 
 
Figure 6: Drug alert information delivered by TreeDashboard-View 
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Figure 7: Drug alert information delivered by ScrollText-View 
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Figure 8: Prescription writer interface 
 
 We also designed an anonymous, computer-based, self-administered survey to measure the 
response time and attitudes of  subjects toward different drug alert interfaces. The details of  the 
enrollment form and questionnaire are shown in Appendix B and C. 
 
Methods 
Setting 
Academic Medical Center 
 The Vanderbilt Clinic (TVC) is the outpatient facility of  Vanderbilt University Medical 
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Center (VUMC). As of  2007, TVC had more than 900 Medical Group physicians on staff, 
comprising over 95 outpatient specialty practices in several locations and provides a full range of  
diagnostic and treatment services. In 2007, TVC had over one million outpatient visits.  
 
Study Population 
 We recruited physician prescribers who were regular RxStar users from Internal 
Medicine/Meds-Peds (combined Internal Medicine and Pediatrics) and who did not participate in 
the Expert Review or Pilot Study phase of  the project. The study’s description and purpose were 
introduced to all target participants by the VUMC Chief  Hospital Informatics Officer (also an 
Internal Medicine physician) via email. Physicians were provided with details about the project. The 
first 12 responders were invited to participate in the study. We used the other respondents as 
alternates if  we could not schedule a session with any of  the original respondent group.  
 Before the study was administered, pilot study and power analysis were conducted to 
estimate the sample size. The study design was approved by the Vanderbilt University Medical 
Center Institutional Review Board.  After receiving all study information, agreement to participate 
was considered informed consent.  
 
Study Environment 
 The study took place in a quiet cubicle to allow the participant to focus on the task of  
deciding whether or not to prescribe a medication, and so that we could simulate the types of  
distractions that predispose to errors in prescribing decisions. Figure 9 shows the study environment, 
including a Clinical Workstation (CWS) and audio instrument. During the study, the participant 
would hear prerecorded background noise simulating a primary adult care unit setting. The noise 
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included phone’s ringing, page’s beeping, and people talking and walking. 
 
 
Figure 9: Simulation lab with CWS workstation and audio-taped distraction instruments 
 
Study Materials 
 We conducted a formal usability test (28) using simulated patient cases to compare the 
effectiveness of  the TreeDashboard-View versus the standard ScrollText-View. Our hypothesis was 
that the TreeDashboard-View would decrease the response time of  the alerts, where the response 
time was defined as the time from the display of  the alerts to the time the prescriber made a 
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decision to override or to cancel the prescription, all while distracted by random but typical clinic 
noise.  
 The two simulated patient cases included patient’s demographics, diagnosis, current 
medications, new prescribed medication, available laboratory information, etc. The patient-related 
information was displayed on the same screen as the prescription writer. The simulated patient cases 
represented different but common adult primary care prescribing situations that were similar in 
complexity. The details of  simulated patient cases used for training and in the study are provided in 
Appendix D. 
 A 10-page study packet included a cover page and a color instruction manual (Appendix E). 
The cover page explained the purpose of  the survey study. The instruction manual provided detailed 
instructions to complete the study. An enrollment form was provided to each participant before the 
study and asked about the participants’ current role, department/unit, years of  RxStar use, and years 
of  StarPanel use.  
 An exit survey was developed to rate both drug alert interfaces with regard to two themes: 
quality of  care and efficiency. Quality of  care questions addressed 4 constructs: 
1. Usefulness of drug alerts 
2. Ability to detect critical information 
3. Ability to accomplish tasks 
4. Is information sufficient to make a prescribing decision 
 Efficiency  consisted of two constructs:  (1) ability to use without additional training; and (2) 
ability to find necessary information when making a prescribing decision. 
 Participants’ responses to the two drug alert interfaces were captured using a 10-point scale 
(1~10) as structured in the Questionnaire for User Interface Satisfaction survey (38), for example, 
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ranging from “1- Hard to detect critical information,” to “10 – Easy to detect critical information”, 
or from “1- Inefficient to accomplish tasks,” to “10 – Efficient to accomplish tasks”, etc. where 
appropriate. Participants were also provided with four free-text comment box questions to solicit 
their thoughts and comments with regard to either drug alert interface. 
 Finally, we graded each prescriber’s response to the alert prototype based on a benchmark 
respfor each alert in each case provided by one senior physician (WCG) and verified by another 
domain expert (both are board-certificated internists).  Grading used a 5-point (0~4) scale based on 
pre-defined rules (see Appendix C). 
0 – No significant interaction or risk 
1 – Slight or minimal risk for interactions 
2 – Moderate risk for interactions (monitoring advisable) 
3 – High risk for interactions (monitoring required and consider alternatives) 
4 – Contraindication 
 
Study Design 
 Figure 10 contains a graphical summary of the overall study design. Before beginning the 
study, each subject completed the enrollment data form, followed by a tutorial that described the 
interfaces and walked the study subject through a Starpanel, RxStar and drug alert prototype session, 
using a training case. Once this case was completed, the subject was automatically randomized to 
one of 4 possible series of screens, as shown below using a two-by-two counter-balanced 
presentation order scheme for case and drug alert interface. 
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Figure 10: The flowchart of  formal usability testing 
 
 Each study took about 40 minutes to complete. After a brief  introduction (1 minute) there 
was a 15-minute training period. During the survey, participants used RxStar/StarPanel on a Clinic 
Workstation (CWS) desktop computer. The subject could only manipulate the keyboard and mouse. 
All participants followed the study instructions without any intervention from researchers. 
 The study was conducted over a four-week period (November 20, 2008 to December 15, 
2008). All participants received a $15 Starbucks gift card or iPod earphone for appreciation upon 
study completion. 
 
Data collection and analysis 
 The survey data were collected electronically. For each patient case that participant 
encountered, we recorded the response time as end time minus the start time where the start time is 
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when drug alert information is populated on the screen, and the end time is when the prescriber 
makes a final decision about prescribing medication by clicking the “submit decision” button. The 
participant was required to make a decision if  prescribing or not for each drug including current 
medication and new mediation. The available decision options included “Yes”, “No” or “Unsure”. 
 The analysis used the response time per drug alert interface. We completed a Wilcoxon 
Paired Signed-Rank Test for a significant difference in the response time taken to make a 
prescription decision between the TreeDashboard-View and controlled ScrollText-View. The same 
analysis was applied to participants’ overall perception toward the two drug alert interfaces. All 
statistical testing was performed using SPSS software, version 14.0 (SPSS). A difference was 
considered present if  testing demonstrated a difference in the groups’ means. 
 Survey sample size was derived from a pilot test of  the interface using three board-certified 
physicians (two from Internal Medicine, one from Family Medicine practice with training and 
experiences in Biomedical Informatics). 
 In the pilot test, the response time using the ScrollText-View was 156 seconds, with a 
standard deviation of  35 seconds; and the mean response time for the TreeDashboard-View was 
144 ± 39 seconds. The difference in response time between the two interfaces was 12 ± 5.6 seconds.  
Sample size was estimated using “Power and Sample Size Calculator” (version 2.1.20, released on 
February 2003) (39). A sample of  12 subjects would provide a power of  90% and an alpha level of  
0.05 in the usability testing to determine a difference in the subjects’ response time. Of  note, the 
pilot used only domain experts, not regular physician prescribers, and presented all cases and drug 
alert interfaces in the same sequence (case 1 ScrollText-View; case 2 TreeDashboard-View). 
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Results 
Subject enrollment 
 We emailed invitation letter to 135 potential participants right after the study was introduced 
via email to all target physicians by the hospital Chief Informatics Officer. 23 physicians signed up 
on-line and 12 physicians completed the study. Since we scheduled the respondent physicians to 
complete the study until we hit our target for 12 testers, the response rate was 17% (23 of 135). Of 
12 physicians who completed the study, 11 were from Internal Medicine and one was from Med-
Peds. Attending and resident physicians were equal in number. 75% of physicians (9 of 12) had 
more than 2 years experience of using RxStar/StarPanel. Table 5 summarizes the descriptive analysis 
results. 
 
Department Subjects Percentage
Internal Medicine 11 91.7 % 
Meds-Peds 1 8.3 % 
Total 12 100 %  
Role Subjects Percentage
Attending 6 50 % 
Resident 6 50 % 
Total 12 100 %  
Yeas of Using 
RxStar 
Subjects Percentage
< 1 3 25 % 
2 5 41.7 % 
3 3 25 % 
4+ 1 8.3 % 
Total 12 100 %  
Yeas of Using 
StarPanel 
Subjects Percentage
< 1 2 16.7 % 
2 3 25 % 
3 3 25 % 
4+ 4 33.3 % 
Total 12 100 %  
 
Table 5: Descriptive analysis of  enrollment distribution 
 
Respo 
 We evaluated the overall response time between ScrollText-View and TreeDashboard-View. 
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The response time for the ScrollText-View was 122 ± 50 seconds, and for the TreeDashboard-View 
was 152 ± 61 seconds (p = .209, α = .05). Figure 11 shows the boxplot of response time of two drug 
alert interfaces  
 
Figure 11: The response time of two drug alert interfaces 
Clinical Appropriateness of  Prescribers’ responses 
 We also evaluated prescribers’ responses with regard to the clinical appropriateness. 
Particularly, we graded each prescriber’s response to the alert prototype based on a benchmark resp 
described in Method section. The result of  the evaluation is summarized in Table 6. The result of  
correct response rate is summarized in Table 7. 
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Number of  prescribers’ responses for each grade of  clinical 
appropriateness 
 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
ScrollText-View 3 4 2 3 1 
TreeDashboard-View 2 5 3 2  
 
* 5-point scale for clinical appropriateness was described earlier. Grade 4 is absolute contraindication. 
 
Table 6: Clinical appropriateness of  prescribers’ responses 
 
Correct Response Rate Drug Alert Interface 
Cut off  by Grade 3 Cut off  by Grade 4 
ScrollText-View 66.7% 91.7% 
TreeDashboard-View 83.3% 100% 
 
Table 7: Correct response rate of  prescribers’ responses 
 
 One subject prescribed medications that were absolutely contraindicated according to drug 
alert information presented by the ScrollText-View. For the indicated patient case, Itraconazole 
should not be prescribed together with Simvastatin and Nexium due to the potential interactions 
between selected azole antifungal and HMG-COA reductase inhibitor (rhabdomyolysis, etc.), and 
between selected azole antifungal and proton pump inhibitor (Itraconazole’s absorption is impaired 
by concurrent administration of  Nexium). Other patient case encounters contained interactions of  
varying degrees. For instance, 3 subjects prescribed medications that contained grade 3 potential 
drug-drug interaction(s) presented by the ScrollText-View. 2 subjects prescribed medications that 
contained grade 3 potential drug-drug interaction(s) presented by the TreeDashboard-View. 
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Prescribers’ perception analysis 
 We evaluated prescribers’ perception on both drug alert interfaces (ScrollText-View and 
TreeDashboard-View). The results of the questionnaire are summarized in Table 8. 
 
ScrollText-View TreeDashboard-
View 
Paired 
Differences 
p-valueQuestionnaire item 
Mean 
score SD 
Mean 
score SD Mean SD  
Quality of care item        
  1. Usefulness of drug alerts 8.58 0.793 9.00 0.739 -0.417 0.669 .059 
  2. Ability to detect critical info. 6.33 1.826 9.08 0.793 -2.750 1.960 .005 
  3. Ability to accomplish tasks 6.67 1.497 8.25 0.754 -1.583 1.676 .001 
  4. Information sufficient to 
make a prescribing decision 8.67 .651 8.50 1.087 0.167 1.030 .705 
Efficiency item        
  1. Ease of use 6.42 1.929 7.58 1.505 -1.167 3.099 .234 
  2. Information easy to find 6.50 1.931 8.17 1.030 -1.667 2.103 .024 
 
Table 8: The result of  prescribers’ perception 
 
 Four questionnaire items addressed proscribers’ perception of  quality of  care. We 
considered that participants’ perception was strongly positive if  the rating score was ≥ 8 on the 10-
point scale. When asked about the usefulness of drug alerts presented (question 1), the response was 
strongly positive with mean of 8.58 ± 0.793 for ScrollText-View, and 9.00 ± 0.739 for 
TreeDashboard-View, respectively. When asked if provided information is sufficient for the 
participant to make prescribing decision (question 6), the response was strongly positive with mean 
of 8.67 ± 0.653 for ScrollText-View, and mean of 8.50 ± 1.087 for TreeDashboard-View. When 
asked about how much the interface could help prescriber to accomplish prescribing task (question 
4), the response was positive with mean of 6.67 ± 1.497 for ScrollText-View, and mean of 8.25 ± 
0.754 for TreeDashboard-View. When asked about the ability to detect critical information (question 
 
 
39
2), the response was surprisingly encouraging with a mean of 9.08 ± 0.793 for TreeDashboard-View. 
 Two questionnaire items addressed proscribers’ perception of  efficiency. When asked about 
the ease of use (question 3), the response was a mean of 6.42 ± 1.929 for ScrollText-View, and a 
mean of 7.58 ± 1.505 for TreeDashboard-View, respectively. When asked if provided information is 
easy to find for making prescribing decision (question 5), the mean response was 6.50 ± 1.931 for 
ScrollText-View, 8.17 ± 1.030 for TreeDashboard-View.  
 We performed Wilcoxon Paired Signed-Rank Test to determine if perception difference on 
questionnaire items existed between the two drug alert interfaces. The results are summarized in 
Table 8.  
 We also asked subjects to comment about different aspects of  the interfaces. When asked 
“How enthusiastic would you be if  VUMC implemented this interface within RxStar in your clinic”, 
11 of  12 subjects felt TreeDashboard-View was more enthusiastic, while one subject felt that it was 
moderate. Some subjects also asked for additional functionalities to be added into TreeDashboard-
View for better performance. Table 10 showed the quotes from the comments we received.  
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Comment box questions Quotes from comments 
How enthusiastic would 
you be if  VUMC 
implemented this interface 
(TreeDashboard-View) 
within RxStar in your 
clinic 
z I would like this format I think this one would be easier to 
incorporate in daily workflow 
z This is a great interface and would be very helpful 
z Much more enthusiastic than the other interface 
z I would like this interface with some minor improvements 
Describe what you like 
about this interface 
(TreeDashboard-View) 
z Key information presented at a glance with color-coding and 
icons that are intuitive. Further information easily available with a 
click or two. 
z Color coding and separation of  data into table-like format All 
actionable items are on the right of  the screen 
z I love the color coding, the faces, the boxes of  colors ... I am a 
visual learner and this set up is very useful for me 
z Clinical effects area (is good) could be expanded 
Describe what you don’t 
like about this interface 
(TreeDashboard-View) 
z What exactly do the happy/sad faces reflect? 
z Maybe I don't remember that there are only 3 levels in your scale 
and that 2 is in the middle. What if  that is 2 out of  6? 
z Smily/frowny faces are distracting and do not add more 
information 
z (I like) ability to review clinical data - switch windows would help
z Option does not exist to alter dosages of  already existing 
medication 
 
Table 9: Quotes from prescribers’ comments on TreeDashboard-View 
 
Discussion 
 We designed and implemented a drug alert presentation application with clinical decision 
support using a commercial drug information knowledgebase. The alerting application was 
seamlessly integrated into an existing outpatient e-Rx system and used to simulate the prescribing 
process. The application contained a computer-based, self-administered survey to measure the 
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response time and attitudes of  prescribers toward different drug alert interfaces aimed to deliver 
multiple drug alerts. 
 After an iterative design phase, we examined four different interfaces for presenting multiple 
drug alerts. Formal usability testing of  the most promising interface (TreeDashboard-View) and 
controlled text-centric ScrollText-View demonstrated that physician prescribers agreed or strongly 
agreed that multiple drug alerts delivered by either were useful for e-Rx practice (both interfaces 
scored > 8.5 on a 10-point scale). Physcian prescribers agreed or strongly agreed that patient-related 
and drug alert information presented by both drug alert interfaces were adequate for them to make 
prescribing decision (both interfaces were scored ≥ 8.5 on a 10-point scale). Our evaluation of  
clinical appropriateness suggested that participants responded to both drug alert presentations 
acceptably. Only one subject prescribed medications that were absolutely contraindicated when 
presented by the ScrollText-View. Other prescribers’ responses pertained to softer interactions of  
varying degrees that may or may not be clinically relevant therefore they are still considered as 
“appropriate”.  
 Formal usability testing also demonstrated that physician prescribers had favorable 
impressions for drug alerts presented by the newly-designed TreeDashboard-View on quality of  
patient care and efficiency when compared to the controlled ScrollText-View. Out of the six 
questions asked for the TreeDashboard-View, five of six were favorable with a score > 8 on a 10 
point scale (1~10). “Ease of use” had a mean score of 7.58 ± 1.505, which is still more favorable 
than the ScrollText-View. Wilcoxon Paired Signed-Rank Test revealed a statistically significant 
difference in participants’ perception in the themes of  quality of  care and efficiency. Physician 
prescribers more likely agreed that the TreeDashboard-View is better than the ScrollText-View to 
detect critical alerts, to accomplish prescribing tasks, and to provide information helpful in making 
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ordering decisions (p < 0.005, 0.011, and 0.024, respectively).  
 The study also showed that physician prescribers’ response time to the same set of  drug 
alerts varied substantially, reflected by a high standard deviation. Although Wilcoxon Paired Signed-
Rank Test failed to reveal statistically significant difference in the response time between the 
ScrollText-View and the TreeDashboard-View (p = .209, α = .05), physician prescribers participating 
in the formal usability testing seemed to spend more time with multiple drug alerts presented by the 
TreeDashboard-View (152 ± 61 versus 122 ± 50 seconds of  ScrollText-View). This is contrary to 
our expectations.  We initially hypothesized that the novel TreeDashboard-View could help physician 
prescribers reduce their response time when evaluating multiple drug alerts. We can speculate an 
explanation based on comments collected from survey questionnaire. Traditionally, most drug alerts 
are delivered in text format using popup windows. Physician prescribers may be more familiar with 
the text-centric ScrollText-View. In contrast, there may be a learning curve to use the more novel 
TreeDashboard-View  interface. This was indicated by prescribers’ comments on negative aspects of 
the interface. Some precribers were confused about the scaling system (coloring schema and 
numbering schema) used in the TreeDashboard-View while an extra click was often required to 
obtain more detailed drug alert information. In this study, both simulated patient cases contained 6 
drug-drug interaction and drug-food interaction alerts. The text-centric ScrollText-View may be still 
sufficient to handle this limited number of multiple drug alerts. In addition, some physicians noted 
that the TreeDashboard-View encouraged physicians to seek more information, thus slowing down 
but potentially providing better quality care during prescribing. An improvement in our scaling 
system and more tutorial/training time may help to reduce the prescribers’ response time to 
TreeDashboard-View in the future study. 
 This study has many limitations that merit discussion. First, the ScrollText-View and the 
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TreeDashboard-View were implemented in a simple manner without the extensive user interface 
refinements of  a commercial interface. Next, physician prescribers may need more time to adopt the 
multiple drug alerts delivered by the newly-designed TreeDashboard-View. Third, this study only 
investigated a single in-house developed e-Rx system with one commercial drug information 
knowledgebase support at one academic medical center. Physician participants were made up of  
housestaff  in Internal Medicine and Med-Peds who were familiar with the in-house developed 
EHR/e-Rx applications in general. It is possible that effects with other systems at other institutes 
may differ from those reported here.  
Of  note, relative small sample size (12 physician prescribers in the formal usability testing) may 
limit statistical analysis in this study. We used convenience sampling (attendings and residents) and 
simulated patient cases that were limited to internal medicine and primary adult care setting, thus 
limiting generalization of  the findings to community practitioners or specialists. In the next round 
of  user interface testing, we may need to expand the design with a larger number of  test subjects to 
allow for learning, and a greater variety of  simulated patient cases selected for each target 
subspecialty likely to use this system. After this round of  testing is completed, we may also want to 
expand the testing to include nurse practitioners as well. 
 Studies have previously demonstrated that e-Rx success depends upon several factors, 
including clinicians’ access to e-Rx systems that is integrated into a single information workflow (1, 9, 
20). In this study, we developed and compared prescribers’ performance using different drug alert 
presentation methods in an existing e-Rx platform, with particular focus on clinical appropriateness 
of  prescribing, the response time, and the prescribers’ preferences. The relative small sample size (12 
physician prescribers), while limiting for statistical purposes, still provides a basis for questions 
regarding the worthiness of  the proposed novel drug alert TreeDashboard-View. 
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Conclusion 
 This study described issues in presenting multiple drug alerts in an outpatient e-Rx 
application integrated into EHR system. A robust model for studying multiple drug alert 
presentation was developed. Several novel drug alert presentation interfaces were introduced. Both 
expert evaluation and usability testing demonstrated that the TreeDashboard-View is viewed more 
favorably than the text-only view. Additional studies should be done on a refined version of this 
interface to improve its impact on accurate decision making and response time. 
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FUTURE WORK 
  
 This study will guide future work on the usability of multiple drug alert presentation 
interfaces in an existing outpatient e-Rx system. After the deployment of  a preferred drug alert 
presentation interface, we hope to iteratively refine the interface design and evaluation of  actual 
prescribing practices. 
 We collected feedback throughout the Expert Review and formal usability survey evaluations. 
After changes are made to the preferred drug alert presentation interface, the testing cycle could 
begin again, e.g., with a new domain expert panel, same or different group of  physicians and nurses, 
to assess the effects of  the changes. This type of  usability testing (Expert Review and formal 
usability survey) can be conducted repeatedly throughout the software life cycle of  e-Rx system. The 
prototypes of  the drug alert presentation and self-administrated survey interfaces developed in this 
study will provide benchmarks against which improvement can be measured in different testing 
scenarios. 
 The outpatient e-Rx system and EHR system used for this study already supports clinical 
decision supports including Drug Allergy Conflicts, Dose Range Checking, Drug-Drug interaction, 
Drug-Food Interaction, Duplicate Ingredient, Geriatric Precautions, and Lactation Precautions 
(provided by commercial FDB drug information knowledgebases). The results of  our findings will 
be presented to the e-Rx development team. After the design of  a preferred drug alert presentation 
interface is finalized, our hope is its integration would be seamless and cost-effective.   
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